Defence Therapeutics
Defence Therapeutics Inc. is a Canadian biotechnology company focused on developing next-generation vaccines and antibody-drug conjugate (ADC) products using its proprietary platform, ACCUM™ technology. The company aims to create effective treatments for catastrophic illnesses such as cancer and infectious diseases through precision delivery of vaccine antigens and ADCs, enhancing efficacy and potency. With a strong focus on innovation, strategic products, and collaborations, Defence Therapeutics is pioneering advances in immuno-oncology, drug delivery technologies, and radiopharmaceuticals.
Industries
Nr. of Employees
small (1-50)
Defence Therapeutics
Patents
Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity
US-12233130-B2
View DetailsCovalently modified antigens for improved immune response and/or stability
US-12150989-B2
View Details
Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity
US-12233130-B2
View DetailsCovalently modified antigens for improved immune response and/or stability
US-12150989-B2
View DetailsProducts
Nuclear-localizing delivery platform (proprietary)
Delivery platform designed to facilitate endosomal escape and transport payloads to the nucleus, increasing intracellular accumulation and creating an intracellular reservoir for controlled payload release.
Optimized endosomal-disrupting anticancer molecule (preclinical)
Chemically optimized molecule derived from the delivery platform exhibiting direct anticancer activity in preclinical models when administered intratumorally or via inhalation routes.
Vaccine platform and antigen‑admix vaccine formulations (preclinical)
Vaccine candidates combining antigen formulations with a delivery moiety to enhance antigen presentation, induce durable memory responses, and treat established tumors in preclinical models; results include peer‑reviewed demonstration of prophylactic protection, antibody-mediated functional activity in vitro, therapeutic synergy with checkpoint inhibitors, and GLP safety/immunogenicity data.
LNP mRNA vaccine formulations (preclinical)
Lipid nanoparticle mRNA vaccine formulations developed with the delivery approach that produced increased antibody responses in preclinical comparisons to standard mRNA formulations.
Accum
Defence Therapeutics’ proprietary bioconjugate and intracellular delivery platform designed to enable efficient endosomal escape for antibody-drug conjugates and other cancer therapeutics.
ACCUM Technology
Proprietary platform technology with proven enhanced drug delivery method for oncology, vaccine development, and nanotechnologies.
Nuclear-localizing delivery platform (proprietary)
Delivery platform designed to facilitate endosomal escape and transport payloads to the nucleus, increasing intracellular accumulation and creating an intracellular reservoir for controlled payload release.
Optimized endosomal-disrupting anticancer molecule (preclinical)
Chemically optimized molecule derived from the delivery platform exhibiting direct anticancer activity in preclinical models when administered intratumorally or via inhalation routes.
Vaccine platform and antigen‑admix vaccine formulations (preclinical)
Vaccine candidates combining antigen formulations with a delivery moiety to enhance antigen presentation, induce durable memory responses, and treat established tumors in preclinical models; results include peer‑reviewed demonstration of prophylactic protection, antibody-mediated functional activity in vitro, therapeutic synergy with checkpoint inhibitors, and GLP safety/immunogenicity data.
LNP mRNA vaccine formulations (preclinical)
Lipid nanoparticle mRNA vaccine formulations developed with the delivery approach that produced increased antibody responses in preclinical comparisons to standard mRNA formulations.
Accum
Defence Therapeutics’ proprietary bioconjugate and intracellular delivery platform designed to enable efficient endosomal escape for antibody-drug conjugates and other cancer therapeutics.
ACCUM Technology
Proprietary platform technology with proven enhanced drug delivery method for oncology, vaccine development, and nanotechnologies.
Services
Design and conduct of in vitro and in vivo efficacy studies in multiple tumor models to evaluate immunogenicity, tumor control, antibody function, cellular mechanisms (dendritic cell cross-presentation and CD8+ T cells), and combination strategies with checkpoint inhibitors; includes GLP study execution for safety and immunogenicity.
cGMP process development, execution of manufacturing dry runs, and final drug product optimization with quality-control steps to support Phase I clinical trials and filings.
Advisory and submission support for clinical trial applications (IND/CTA) and interactions with regulatory authorities to enable initiation of first‑in‑human studies.
Program management and negotiation support for collaborative research, development partnerships, and licensing arrangements to advance technologies to partners and sponsors.
Design and conduct of in vitro and in vivo efficacy studies in multiple tumor models to evaluate immunogenicity, tumor control, antibody function, cellular mechanisms (dendritic cell cross-presentation and CD8+ T cells), and combination strategies with checkpoint inhibitors; includes GLP study execution for safety and immunogenicity.
cGMP process development, execution of manufacturing dry runs, and final drug product optimization with quality-control steps to support Phase I clinical trials and filings.
Advisory and submission support for clinical trial applications (IND/CTA) and interactions with regulatory authorities to enable initiation of first‑in‑human studies.
Program management and negotiation support for collaborative research, development partnerships, and licensing arrangements to advance technologies to partners and sponsors.
Expertise Areas
- Drug delivery platform development (nuclear-localizing approaches)
- Antibody-drug conjugate (ADC) design and optimization
- Vaccine development (protein and mRNA modalities)
- Preclinical immuno‑oncology and murine tumor-model studies
Key Technologies
- Nuclear‑localizing delivery mechanisms
- Antibody‑drug conjugation techniques
- Endosomal escape / membrane‑disrupting moieties
- Lipid nanoparticle (LNP) mRNA delivery
News & Updates
The company discusses its vaccine development efforts and progress.
Announcement of clinical trial plans for Accum™ technology and related therapeutics.
Received USPTO allowance for patent covering innovative ADC platform.
Participation in the 2025 Bio International Convention to showcase innovations.
Publication in Cancer Science journal validating the efficacy of Accum®-E7 vaccine, demonstrating its prophylactic and therapeutic potential, safety, and immunogenicity.
The company discusses its vaccine development efforts and progress.
Announcement of clinical trial plans for Accum™ technology and related therapeutics.
Received USPTO allowance for patent covering innovative ADC platform.
Participation in the 2025 Bio International Convention to showcase innovations.
Publication in Cancer Science journal validating the efficacy of Accum®-E7 vaccine, demonstrating its prophylactic and therapeutic potential, safety, and immunogenicity.